Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Zura Bio ( (ZURA) ) has issued an announcement.
On May 21, 2025, Zura Bio Limited held its Annual General Meeting of Shareholders where all three proposals presented were addressed. The shareholders elected nine directors to the board, ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and did not need to vote on the adjournment proposal as the first two proposals were approved.
The most recent analyst rating on (ZURA) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.
Spark’s Take on ZURA Stock
According to Spark, TipRanks’ AI Analyst, ZURA is a Neutral.
Zura Bio’s overall stock score is driven by significant financial challenges, including no revenue generation and consistent losses despite a strong cash position and no debt. While technical indicators suggest some short-term bullish trends, the negative P/E ratio and lack of dividends underscore the valuation concerns. The company’s ability to generate revenue and improve operational efficiency will be crucial for future performance.
To see Spark’s full report on ZURA stock, click here.
More about Zura Bio
Average Trading Volume: 386,471
Technical Sentiment Signal: Sell
Current Market Cap: $64.35M
Find detailed analytics on ZURA stock on TipRanks’ Stock Analysis page.